Omega-3处方药市场规模、份额和趋势分析报告：按分销渠道（医院、在线药房）、应用（高甘油三酯血症）、药物（Vascepa、Lovaza）、地区、细分市场预测2022-2030

Omega-3 处方药市场增长和趋势

Grand View Research, Inc. 的一份新报告预测，到 2030 年，全球 omega-3 处方药市场规模将达到 25.2 亿美元，在预测期内的复合年增长率为 8.27%。该行业的增长是由于心血管疾病（CVD）病例数量的增加和饮食的变化。现在已知血液甘油三酯水平升高与心血管疾病风险增加有关。根据欧洲心脏病学会 2021 年的数据，每年有 1790 万人死于 CVD，使其成为全球主要死因。此外，随着产品在药品中的应用潜力不断扩大，预计行业参与者推出基于 omega-3 的药物将促进其增长。

例如，2020 年，美国 FDA 批准了美国 Amarin 生产的 omega-3 药物 VASCEPA 的新心血管适应症和扩大标籤。增加甘油三酯使动脉变窄，增加心肌梗塞和中风的风险。胰腺炎是胰腺的炎症，也可能由极高的值引起。糖尿病和肥胖症导致甘油三酯水平升高，这是一个常见问题。平均 25% 的美国成年人血液中的酒精含量处于临界水平。 Omega-3 脂肪酸药物仅适用于 500 mg/dl 或更高水平的甘油三酯，这是美国 FDA 批准的。在 COVID-19 大流行期间，Omega-3 处方药出现了重大的市场变动。

这是由于其在 CVD 患者管理中的重要作用。例如，2021 年 8 月，Woodward Pharma Services LLC宣布已从GlaxoSmithKline手中收购 LOVAZA。该公司还旨在教育消费者和医疗保健提供者，以促进该产品的更高采用率。此外，针对降低甘油三酯进行了多项研发研究，对 17 项提高甘油三酯水平的有组织、随机临床试验结果的综合分析表明，处方 omega-3 脂肪酸药物降低了 20%~30%建议减少。预计这将产生较高的产品需求。

Omega-3 处方药市场报告亮点

由于 Vacepa 已获 FDA 批准用于降低 CVD 风险的患者，因此 Vacepa 药物部分将在 2021 年占销售额的最大份额。

通过应用，预计高甘油三酯血症部分将在预测期内实现最快的增长率。

这种增长是由于甘油三酯水平升高的患者使用 omega-3 处方药的增加。

2021 年，北美在全球行业中占主导地位，因为 CVD 是该地区的首要死因和目标疾病的高流行率。

主要参与者正专注于利用现有药物开发先进的新型剂型，以满足不断增长的需求并提供有效的治疗选择。

内容

第 1 章 Omega-3 处方药市场：研究方法和范围

• 调查方法
• 调查假设
• 信息采购
  • 购买的数据库
  • GVR 内部数据库
  • 辅助信息
  • 初步调查
  • 初步调查的内容
• 信息或数据分析
  • 数据分析模型
• 市场製定和验证
• 型号详情
  • 商品流向分析
    • 方法 1：商品流通方法
  • 量价分析（模型 2）
    • 方法 2：体积分析
    • 收入建模
• 辅助信息列表
• 主要信息列表

第 2 章 Omega-3 处方药市场：执行摘要

• 市场概览

第 3 章 Omega-3 处方药市场：行业展望

• 市场系列展望
  • 母公司市场展望
• 绘製渗透率和增长前景
• 市场动态
  • 市场驱动因素分析
    • 心血管疾病、肥胖症和高甘油三酯血症的患病率不断上升
    • 开髮用于治疗相关疾病的新型治疗剂
    • 对免疫补充剂的担忧日益增加
    • 久坐不动的生活方式、倾向于在家工作、缺乏锻炼
  • 市场约束分析
    • 与 omega-3 处方药相关的高成本
• 波特五力分析
• 按因素（政法、经济、技术）进行 SWOT 分析
• 监管框架
• 用户视角分析

第 4 章 Omega-3 处方药市场：竞争格局

• 主要市场参与者的近期趋势和影响分析
  • Ansoff Matrix
• Major deals &strategic alliances analysis
  • 合资企业
  • 许可和合作伙伴关係
  • 技术合作
• 公司/竞争对手分类
• 供应商情况
  • 主要分销商和渠道合作伙伴列表
  • 主要客户
• 上市公司
  • 公司市场分析
• 私人公司
  • 主要初创企业列表
  • 本地网络地图

第 5 章 Omega-3 处方药市场：医药业务分析

• 定义和范围
• 类型市场份额分析，2021 年和 2030 年
• 2018-2030 年全球 Omega-3 处方药市场，按药物分类
• 2018-2030 年市场规模和预测、趋势分析
  • 维塞帕
  • 洛瓦萨
  • 其他

第 6 章 Omega-3 处方药市场：应用业务分析

• 定义和范围
• 2021 年和 2030 年应用市场份额分析
• 2018-2030 年全球 Omega-3 处方药市场（按应用）
• 2018-2030 年市场规模和预测、趋势分析
  • 高甘油三酯血症
  • 其他

第 7 章 Omega-3 处方药市场：分销渠道业务分析

• 定义和范围
• 2021 年和 2030 年应用市场份额分析
• 2018-2030 年全球 Omega-3 处方药市场，按分销渠道
• 2018-2030 年市场规模和预测、趋势分析
  • 医院药房
  • 零售药房
  • 在线药店

第 8 章 Omega-3 处方药市场：区域业务分析

• 定义和范围
• 2021 年和 2030 年区域市场份额分析
• 区域市场信息中心
• 区域市场概况
• 按因素（政治和法律、经济和技术）进行 SWOT 分析
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 多边环境协定
• 2021-2030 年市场规模、预测、趋势分析
• 北美
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 意大利
  • 西班牙
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 多边环境协定
  • 南非
  • 沙特阿拉伯
  • 阿拉伯联合酋长国

第 9 章 Omega-3 处方药市场：公司概况

• 公司简介
  • Abbott
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Amarin Pharmaceuticals Ireland Limited
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • GSK plc（GlaxoSmithKline Plc）
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Natrapharm, Inc.（Patriot Pharmaceutical Corp.）
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Viatris Inc.
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Grupo Ferrer Internacional, SA
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Camber Pharmaceuticals, Inc.
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Dr. Reddy's Laboratories Ltd.
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Zydus Group
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措
  • Hikma Pharmaceuticals PLC
    • 公司概况
    • 财务表现
    • 产品基准
    • 战略举措

Omega 3 Prescription Drugs Market Growth & Trends:

The global omega 3 prescription drugs market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 8.27% over the forecast period, according to a new report by Grand View Research, Inc. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.

Omega 3 Prescription Drugs Market Report Highlights:

• The vascepa drug segment accounted for the largest revenue share in 2021 as vascepa is approved by the FDA for use in patients for reducing the risk of CVD

• By application, the hypertriglyceridemia segment is expected to register the fastest growth rate over the forecast period

• The growth can be attributed to the increasing use of omega 3 prescription medications for patients with elevated triglyceride levels

• North America dominated the global industry in 2021 owing to the high prevalence of target diseases, with CVD being the leading cause of death in the region

• Key players are focusing on developing advanced and novel dosage forms from existing drugs to meet the rising demand and provide efficient treatment options

Table of Contents

Chapter 1 Omega 3 Prescription Drugs Market: Methodology and Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates and forecast timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.6.2 Volume price analysis (model 2)
    • 1.6.2.1 Approach 2: Volume price analysis
    • 1.6.2.2 Revenue modeling
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources

Chapter 2 Omega 3 Prescription Drugs Market: Executive Summary

• 2.1 Market summary

Chapter 3 Omega 3 Prescription Drugs Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Increasing prevalence of cardiovascular diseases, obesity and hypertriglyceridemia
    • 3.3.1.2 Development of novel drugs for treatment of related disease condition
    • 3.3.1.3 Rising concerns related to immunity supplements
    • 3.3.1.4 Sedentary lifestyles, the trend toward working from home, and a lack of physical activity
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 High cost associated with omega 3 prescription drugs
• 3.4 Porter's Five Forces Analysis
• 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.6 Regulatory Framework
• 3.7 User Perspective Analysis

Chapter 4 Omega 3 Prescription Drugs Market: Competitive Landscape

• 4.1 Recent developments & impact analysis, by key market participants
  • 4.1.1 Ansoff Matrix
• 4.2 Major deals & strategic alliances analysis
  • 4.2.1 Joint Ventures
  • 4.2.2 Licensing and Partnerships
  • 4.2.3 Technological Collaborations
• 4.3 Company/Competition Categorization
• 4.4 Vendor Landscape
  • 4.4.1 List Of Key Distributors and Channel Partners
  • 4.4.2 Key Customers
• 4.5 Public Companies
  • 4.5.1 Company Market Position Analysis
• 4.6 Private Companies
  • 4.6.1 List Of Key Emerging Companies
  • 4.6.2 Regional Network Map

Chapter 5 Omega 3 Prescription Drugs Market: Drug Business Analysis

• 5.1 Definition and Scope
• 5.2 Type Market Share Analysis, 2021 & 2030
• 5.3 Global Omega 3 Prescription Drugs Market, By Drugs, 2018 to 2030
• 5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1 Vascepa
    • 5.4.1.1 Vascepa Market 2018 - 2030 (USD Million)
  • 5.4.2 Lovaza
    • 5.4.2.1 Lovaza Market, 2018 - 2030 (USD Million)
  • 5.4.3 Others
    • 5.4.2.3 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Omega 3 Prescription Drugs Market: Application Business Analysis

• 6.1 Definition and Scope
• 6.2 Application Market Share Analysis, 2021 & 2030
• 6.3 Global Omega 3 Prescription Drugs Market, By Application, 2018 to 2030
• 6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1 Hypertriglyceridemia
    • 6.4.1.1 Hypertriglyceridemia Market 2018 - 2030 (USD Million)
  • 6.4.2 Others
    • 6.4.2.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7 Omega 3 Prescription Drugs Market: Distribution Channel Business Analysis

• 7.1 Definition and Scope
• 7.2 Application Market Share Analysis, 2021 & 2030
• 7.3 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 to 2030
• 7.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 7.4.1 Hospital Pharmacy
    • 7.4.1.1 Hospital Pharmacy Market 2018 - 2030 (USD Million)
  • 7.4.2 Retail Pharmacy
    • 7.4.2.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.4.2 Online Pharmacy
    • 7.4.2.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8 Omega 3 Prescription Drugs Market: Regional Business Analysis

• 8.1 Definition & Scope
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 Regional Market Dashboard
• 8.4 Regional Market Snapshot
• 8.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 8.5.1 North America
  • 8.5.2 Europe
  • 8.5.3 Asia Pacific
  • 8.5.4 Latin America
  • 8.5.5 MEA
• 8.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
• 8.7 North America
  • 8.7.1 North America Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.7.2 U.S.
    • 8.7.2.1 U.S. Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.7.3 Canada
    • 8.7.3.1 Canada Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.8 Europe
  • 8.8.1 Europe Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.2 U.K.
    • 8.8.2.1 U.K. Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.3 Germany
    • 8.8.3.1 Germany Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.4 France
    • 8.8.4.1 France Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.5 Italy
    • 8.8.5.1 Italy Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.6 Spain
    • 8.8.6.1 Spain Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.9 Asia Pacific
  • 8.9.1 Asia-Pacific Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.2 Japan
    • 8.9.2.1 Japan Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.3 China
    • 8.9.3.1 China Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.4 India
    • 8.9.4.1 India Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.5 Australia
    • 8.9.5.1 Australia Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.6 South Korea
    • 8.9.6.1 South Korea Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.10 Latin America
  • 8.10.1 Latin America Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.2 Brazil
    • 8.10.2.1 Brazil Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.3 Mexico
    • 8.10.3.1 Mexico Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.4 Argentina
    • 8.10.4.1 Argentina Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.11 MEA
  • 8.11.1 MEA Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.2 South Africa
    • 8.11.2.1 South Africa Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.3 Saudi Arabia
    • 8.11.3.1 Saudi Arabia Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.4 UAE
    • 8.11.4.1 UAE Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)

Chapter 9 Omega 3 Prescription Drugs Market: Company Profiling

• 9.1 Company Profiles
  • 9.1.1. Abbott
    • 9.1.1.1 Company overview
    • 9.1.1.2 Financial performance
    • 9.1.1.3 Product benchmarking
    • 9.1.1.4 Strategic Initiatives
  • 9.1.2. Amarin Pharmaceuticals Ireland Limited
    • 9.1.2.1 Company overview
    • 9.1.2.2 Financial performance
    • 9.1.2.3 Product benchmarking
    • 9.1.2.4 Strategic Initiatives
  • 9.1.3. GSK plc (GlaxoSmithKline Plc)
    • 9.1.3.1 Company overview
    • 9.1.3.2 Financial performance
    • 9.1.3.3 Product benchmarking
    • 9.1.3.4 Strategic Initiatives
  • 9.1.4. Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
    • 9.1.4.1 Company overview
    • 9.1.4.2 Financial performance
    • 9.1.4.3 Product benchmarking
    • 9.1.4.4 Strategic Initiatives
  • 9.1.5. Viatris Inc.
    • 9.1.5.1 Company overview
    • 9.1.5.2 Financial performance
    • 9.1.5.3 Product benchmarking
    • 9.1.5.4 Strategic Initiatives
  • 9.1.6. Grupo Ferrer Internacional, S.A.
    • 9.1.6.1 Company overview
    • 9.1.6.2 Financial performance
    • 9.1.6.3 Product benchmarking
    • 9.1.6.4 Strategic Initiatives
  • 9.1.7. Camber Pharmaceuticals, Inc.
    • 9.1.7.1 Company overview
    • 9.1.7.2 Financial performance
    • 9.1.7.3 Product benchmarking
    • 9.1.7.4 Strategic Initiatives
  • 9.1.8 Dr. Reddy's Laboratories Ltd.
    • 9.1.8.1 Company overview
    • 9.1.8.2 Financial performance
    • 9.1.8.3 Product benchmarking
    • 9.1.8.4 Strategic Initiatives
  • 9.1.9 Zydus Group
    • 9.1.9.1 Company overview
    • 9.1.9.2 Financial performance
    • 9.1.9.3 Product benchmarking
    • 9.1.9.4 Strategic Initiatives
  • 9.1.10 Hikma Pharmaceuticals PLC
    • 9.1.10.1 Company overview
    • 9.1.10.2 Financial performance
    • 9.1.10.3 Product benchmarking
    • 9.1.10.4 Strategic Initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Omega 3 Prescription Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 6 Global Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 7 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 10 North America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 11 North America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 13 U.S. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 14 U.S. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 16 Canada Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 17 Canada Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Europe Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 20 Europe Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 21 Europe Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 U.K. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 23 U.K. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 24 U.K. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 Germany Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 26 Germany Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 27 Germany America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 France Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 29 France Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 30 France Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 32 Spain Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 33 Spain Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Italy Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 35 Italy Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 36 Italy Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Asia Pacific Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 38 Asia Pacific Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 39 Asia Pacific Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 China Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 42 China Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 43 China Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Japan Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 45 Japan Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 46 Japan Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 India Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 48 India Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 49 India Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 South Korea Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 51 South Korea Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 52 South Korea Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Australia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 54 Australia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 55 Australia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Latin America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 57 Latin America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 58 Latin America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 59 Latin America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Brazil Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 61 Brazil Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 62 Brazil Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Mexico Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 64 Mexico Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 65 Mexico Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Argentina Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 67 Argentina Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 68 Argentina Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 MEA Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 70 MEA Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 71 MEA Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 72 MEA Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 South Africa Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 74 South Africa Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 75 South Africa Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Saudi Arabia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 77 Saudi Arabia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 UAE Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 80 UAE Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 81 UAE Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Omega 3 Prescription Drugs Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Omega 3 Prescription Drugs Market: Drug Movement Analysis
• Fig. 16 Vascepa market, 2018 - 2030 (USD Million)
• Fig. 17 Lovaza market, 2018 - 2030 (USD Million)
• Fig. 18 Others market, 2018 - 2030 (USD Million)
• Fig. 19 Omega 3 Prescription Drugs Market: Application Movement Analysis
• Fig. 20 Hypertriglyceridemia market, 2018 - 2030 (USD Million)
• Fig. 21 Others market, 2018 - 2030 (USD Million)
• Fig. 22 Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
• Fig. 23 Hospital Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 24 Retail Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 25 Online Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 26 Regional Marketplace: Key Takeaways
• Fig. 27 Regional Outlook, 2018 & 2030
• Fig. 28 Regional Market Dashboard
• Fig. 29 Regional Market Place: Key Takeaways
• Fig. 30 North America, SWOT Analysis
• Fig. 31 Europe, SWOT Analysis
• Fig. 32 Asia Pacific, SWOT Analysis
• Fig. 33 Latin America, SWOT Analysis
• Fig. 34 MEA, SWOT Analysis
• Fig. 35 North America
• Fig. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 37 U.S.
• Fig. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 39 Canada
• Fig. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 41 Europe
• Fig. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 43 U.K.
• Fig. 44 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 45 Germany
• Fig. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 47 France
• Fig. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 49 Italy
• Fig. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 51 Spain
• Fig. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 53 Asia Pacific
• Fig. 54 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 55 Japan
• Fig. 56 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 57 China
• Fig. 58 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 59 India
• Fig. 60 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 61 Australia
• Fig. 62 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 63 South Korea
• Fig. 64 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 65 Latin America
• Fig. 66 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 67 Brazil
• Fig. 68 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 69 Mexico
• Fig. 70 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 71 Argentina
• Fig. 72 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 73 MEA
• Fig. 74 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 75 South Africa
• Fig. 76 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia
• Fig. 78 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 79 UAE
• Fig. 80 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 81 Strategy Mapping